Information Provided By: 
Fly News Breaks for June 15, 2018
TXMD
Jun 15, 2018 | 05:20 EDT
JPMorgan analyst Chris Schott started TherapeuticsMD with an Overweight rating and $11 price target. The analyst believes TX-001 and Imvexxy represent "significant" long-term opportunities. He sees peak sales of $750M for TX-001 and thinks Imvexxy can gain 20%-plus of the severe dyspareunia market over time. Schott sees TherapeuticsMD as well positioned in the women's health space.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
